Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B surface antigen + ADVAX-3
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hepatitis B surface antigen + ADVAX-3 is an investigational recombinant protein subunit vaccine developed by Vaxine for the prevention and potential treatment of hepatitis B virus (HBV) infection. The vaccine combines recombinant hepatitis B surface antigen (HBsAg) with Vaxine's proprietary ADVAX-3 adjuvant system. ADVAX-3 is a combination adjuvant consisting of delta inulin (Advax), a unique polysaccharide that enhances immune responses without significant inflammation, and a Toll-like receptor 9 (TLR9) agonist, typically a CpG oligonucleotide. This combination is designed to induce potent, long-lasting humoral and Th1-biased cellular immunity, addressing the limitations of traditional alum-adjuvanted HBV vaccines, particularly in non-responders or for therapeutic applications in chronic HBV. The candidate has been evaluated in Phase 1 clinical trials to assess safety, tolerability, and immunogenicity.
- Other names
- hepatitis B surface antigen + ADVAX-3HBV-Advax-3HBV-Advax3HBV-Advax 3HBsAg + Advax-3
02
Targets
HBsAg (Hepatitis B surface antigen)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on hepatitis B surface antigen + ADVAX-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B surface antigen + ADVAX-3.